Mantle cell lymphoma (MCL) is an aggressive histotype of B-cell non-Hodgkin lymphoma. The disease has no known cure, which prompts the urgent need for novel therapeutic agents. Chromosomal region maintenance 1 (CRM1) may play a role in human neoplasia and serve as a novel target of cancer treatment. This study summarizes MCL pathogenesis and determines the involvement of CRM1 in the regulation of several vital signaling pathways contributing to MCL pathogenesis, including the pathways of cell cycle progression, DNA damage response, phosphoinositide kinase-3, nuclear factor-κB activation, and chromosomal stability. A preclinical study is also presented to compare the CRM1 status in MCL cell lines and primary MCL cells with normal B cells, as well as the therapeutic efficiency of CRM1 inhibition in MCL in vitro and in vivo, which make these agents potential targets of novel MCL treatments.

Two modifications of the α and β forms of propyl mercaptan nickel(II) cluster, [Ni6(SCH2CH2CH3)12], have been synthesized and their crystal structures have been determined by single-crystal X-ray diffraction. The alkyl groups are away from Ni6 ring in α form whereas they are near to the Ni atom in β form. The distance of Ni-H in β form [2.576(5) Å] is much shorter than that in α form [3.101(2) Å]. In the crystal lattice of β form, the whole structure forms a flower shape.